





OPEN

Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

Maria L. Lozano , Maria E. Mingot-Castellano, María M. Perera, Isidro Jarque, Rosa M. Campos-Alvarez, Tomás J. González-López, Gonzalo Carreño-Tarragona, Nuria Bermejo, Maria F. Lopez-Fernandez, Aurora de Andrés, David Valcarcel, Luis F. Casado-Montero, Maria T. Alvarez-Roman, María I. Orts, Silvana Novelli, Nuria Revilla , Jose R. González-Porras, Estefanía Bolaños, Manuel A. Rodríguez-López, Elisa Orna-Montero & Vicente Vicente


Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-019-53209-y>, published online 13 November 2019

The original version of this Article contained errors in Figures 1 and 2.

In Figure 1, the y-axis label, “Proportion of patients that maintain TFR” was incorrectly given as “Patients that maintained TFR (%)”. In Figure 2, the y-axis label, “Proportion of patients that achieve TFR” was incorrectly given as “Patients that achieved TFR (%)”. The original Figures 1 and 2 and accompanying legends appear below.


The original Article has been corrected.

Published online: 13 August 2021




At risk: Cumulative loss of TFR events	Day 0	Day 450	Day 900	Day 1350
Romiplostim	23:0	20:1	11:4	3:5
Eltrombopag	12:0	10:0	5:1	2:2
Switched	6:0	5:0	3:1	1:2

Figure 1. Probability of maintaining therapy free responses (TFR) upon TPO-RA discontinuation. Kaplan–Meier plot showing the estimated probability of TFR in patients who discontinue TPO-RA for reasons other than lack of efficacy and being followed for a minimum of 6 months (n = 41). Patients who died while on TPO-RA therapy were not included in the study. Solid black line represents patients that received only romiplostim (n = 23); solid grey line represents patients that received only eltrombopag (n = 12), and dashed black line represents patients that switched TPO-RA (n = 6). The number of patients that discontinue TPO therapy (“at risk”) and the cumulative loss of TFR events at time points are presented for each group below the figure.



At risk: Cumulative TFR events	Day 0	Day 450	Day 900	Day 1350	Day 1800
Romiplostim	41:0	28:11	19:18	7:21	1:21
Eltrombopag	41:0	32:7	26:10	13:10	3:10
Rom-Elt	13:0	12:0	10:2	6:2	2:2
Elt-Rom	26:0	20:0	17:0	8:2	1:2



At risk: Cumulative TFR events	Day 0	Day 450	Day 900	Day 1350	Day 1800
Romiplostim	29:0	21:6	17:10	6:13	1:13
Eltrombopag	24:0	18:4	15:6	7:6	2:6
Rom-Elt	8:0	7:0	6:1	4:1	1:1
Elt-Rom	21:0	15:0	13:0	7:1	1:1

Figure 2. Probability of achieving therapy free responses (TFR). Proportion of patients achieving TFR within the whole cohort (n = 121) included in the study (panel a), and in those with chronic ITP (panel b). TFR was defined as the ability of a patient to discontinue TPO-RA as platelet counts > 50 × 10⁹/l for at least 6 months in the absence of any therapies meant to increase platelet counts. Patients who died while on TPO-RA therapy were not included in the study. Solid black line represents patients that received only romiplostim (Panel a, n = 41; Panel b, n = 29). Solid grey line represents patients that received only eltrombopag (Panel a, n = 41; Panel b, n = 24). Dashed black line represents patients that initiated romiplostim and switched to eltrombopag (Panel a, n = 13; Panel b, n = 8). Dashed grey line represents patients that initiated eltrombopag and switched to romiplostim (Panel a, n = 26; Panel b, n = 21). The number of patients under TPO therapy (“at risk”) and the cumulative TFR at time points are presented for each group below each figure.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021